These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19464529)

  • 1. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.
    Nakouzi A; Zhang T; Oscarson S; Casadevall A
    Vaccine; 2009 Jun; 27(27):3513-8. PubMed ID: 19464529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
    Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A
    Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
    Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
    Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
    J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
    May RJ; Beenhouwer DO; Scharff MD
    J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
    Mukherjee J; Kozel TR; Casadevall A
    J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
    Beenhouwer DO; May RJ; Valadon P; Scharff MD
    J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
    Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
    Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
    Fleuridor R; Lees A; Pirofski L
    J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.
    Casadevall A; DeShaw M; Fan M; Dromer F; Kozel TR; Pirofski LA
    Infect Immun; 1994 Sep; 62(9):3864-72. PubMed ID: 8063403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
    Nussbaum G; Anandasabapathy S; Mukherjee J; Fan M; Casadevall A; Scharff MD
    Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semisynthetic Glycoconjugate Vaccine Candidates against
    Crawford CJ; Liporagi-Lopes L; Coelho C; Santos Junior SR; Moraes Nicola A; Wear MP; Vij R; Oscarson S; Casadevall A
    ACS Infect Dis; 2024 Jun; 10(6):2089-2100. PubMed ID: 38819951
    [No Abstract]   [Full Text] [Related]  

  • 13. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
    Brandt S; Thorkildson P; Kozel TR
    Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
    Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
    Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.
    Maitta RW; Datta K; Lees A; Belouski SS; Pirofski LA
    Infect Immun; 2004 Jan; 72(1):196-208. PubMed ID: 14688097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
    Cleare W; Cherniak R; Casadevall A
    Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
    Netski D; Kozel TR
    Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
    Duro RM; Netski D; Thorkildson P; Kozel TR
    Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
    Maitta RW; Datta K; Pirofski LA
    Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
    Devi SJ; Schneerson R; Egan W; Ulrich TJ; Bryla D; Robbins JB; Bennett JE
    Infect Immun; 1991 Oct; 59(10):3700-7. PubMed ID: 1716613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.